Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries

ConclusionWhen used according to clinical practice in the Nordic countries, the observed first-year absolute risk of hospitalized infection was doubled for secukinumab compared with adalimumab. This excess risk seemed largely explained by confounding by indication.
Source: Rheumatology - Category: Rheumatology Source Type: research